My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

51.78 -0.36 (-0.69%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

39 40 Next >

Move Over Magnificent 7, Say Hello to the GRANOLAS ↗

February 22, 2024

Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.

Via InvestorPlace

Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests ↗

February 20, 2024

The FDA put studies in eczema and asthma treatment on clinical hold.

Via Investor's Business Daily

Cruising For A Bruising ↗

February 18, 2024

We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft...

Via Talk Markets

Topics Economy

2 Healthcare Stocks You Can Buy and Hold for the Next Decade ↗

February 16, 2024

Don't count these companies out too soon.

Via The Motley Fool

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness ↗

February 15, 2024

Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.

Via InvestorPlace

Why the dividend investor may take a look at NASDAQ:SNY. ↗

February 14, 2024

Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics.

Via Chartmill

NASDAQ:SNY is an undervalued gem with solid fundamentals. ↗

February 14, 2024

SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Sanofi's Earnings Outlook ↗

January 31, 2024

Via Benzinga

The 3 Biotech Stocks That Could Make Your February Unforgettable ↗

February 15, 2024

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

Via InvestorPlace

What's Going On Eli Lilly Stock Thursday? ↗

February 08, 2024

Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews.

Via Benzinga

Novo Nordisk To Up Production Capacity As Parent Buys Catalent ↗

February 05, 2024

NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash.

Via Investor's Business Daily

CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development ↗

February 05, 2024

Click here to learn more about CytoReason and how to invest through OurCrowd.

Via Benzinga

Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets ↗

February 03, 2024

Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.

Via Talk Markets

Analyzing NASDAQ:SNY's Dividend Potential. ↗

January 24, 2024

Balancing Dividends and Fundamentals: The Case of SANOFI-ADR (NASDAQ:SNY).

Via Chartmill

Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? ↗

February 02, 2024

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.

Via Benzinga

Sanofi (SNY) Q4 2023 Earnings Call Transcript ↗

February 01, 2024

SNY earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 01, 2024

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.

Via Benzinga

French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs ↗

February 01, 2024

Sanofi reports Q4 operating income of €2.6B, down 5.2%. Revenues rise 1.8% to €10.92B, Specialty Care grows 13.7%, Dupixent sales surge.

Via Benzinga

Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't. ↗

February 01, 2024

The company missed total sales and earnings expectations.

Via Investor's Business Daily

Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year ↗

February 01, 2024

After ending January with modest gains, the major averages now look to earnings catalysts to drive momentum, with futures higher in first trading session of February.

Via Benzinga

MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

February 01, 2024

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 90 points on Thursday.

Via Benzinga

Earnings Scheduled For February 1, 2024 ↗

February 01, 2024

Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...

Via Benzinga

Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗

January 29, 2024

An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.

Via Benzinga

Topics Artificial Intelligence

Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation ↗

January 26, 2024

FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients.

Via Benzinga

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

January 25, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx ↗

January 23, 2024

The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency.

Via Investor's Business Daily

French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B ↗

January 23, 2024

Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected...

Via Benzinga

Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project ↗

January 23, 2024

Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO.

Via Benzinga

Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades ↗

January 22, 2024

HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.

Via Benzinga

Time to buy these 3 healthcare companies that raised revenue guidance?

January 16, 2024

The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance.

Via MarketBeat

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.